secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001193125-26-144569
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma achieves preclinical milestone with Boehringer Ingelheim; $7.5M payment due May 2026
--------------------------------------------------------------------------------

- Boehringer Ingelheim approved selection of first compound for lead optimization under April 2025 collaboration.
- Milestone triggers $7.5M payment to Cue Biopharma, expected in May 2026.
- Collaboration targets differentiated B cell depletion molecules including CUE-501.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526144569/0001193125-26-144569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526144569/cue-20260401.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-144569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer